Brokerages Set AngioDynamics, Inc. (NASDAQ:ANGO) PT at $19.33

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned an average rating of “Hold” from the five ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $19.3333.

Several research firms have recently commented on ANGO. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Revenue beat and sustained med‑tech growth — AngioDynamics reported roughly $78M in Q3 sales (above estimates) and management highlighted sustained double‑digit growth in its med‑tech businesses, a primary driver cited for upside. AngioDynamics Q3 press release / slide deck
• Positive Sentiment: Company raised full‑year 2026 guidance — management upgraded its outlook following the quarter, which is a near‑term positive catalyst for the stock as investors often reward upward revisions. TipRanks: AngioDynamics raises 2026 guidance
• Neutral Sentiment: Conference call details available — management commentary in the Q3 earnings call and transcripts add color on product performance and margin plans; useful for investors but not a single definitive signal. Seeking Alpha earnings call transcript
• Neutral Sentiment: Elevated trading volume — volume was materially above the average, indicating active re‑pricing and investor interest; this amplifies intraday moves but doesn’t by itself indicate direction. MarketBeat: ANGO trading data
• Negative Sentiment: Mixed/complex earnings metrics — outlets and the call reported differing EPS figures (some showed an EPS miss on certain measures), creating confusion over the underlying profitability picture and raising short‑term risk. InsiderMonkey: earnings call transcript noting EPS miss
• Negative Sentiment: Profitability still mixed — the company reported negative net margin and negative return on equity in the period, signaling that despite top‑line strength, margin improvement and consistent GAAP profitability remain issues for longer‑term valuation. Zacks: Q3 loss and margin data

Institutional Trading of AngioDynamics

A number of hedge funds and other institutional investors have recently modified their holdings of ANGO. Goldman Sachs Group Inc. lifted its stake in shares of AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares in the last quarter. Jane Street Group LLC raised its holdings in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 34,054 shares during the period. Legal & General Group Plc raised its holdings in AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares during the period. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of AngioDynamics by 15.8% in the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 13,217 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $10.31 on Friday. The firm has a market capitalization of $424.98 million, a price-to-earnings ratio of -13.75 and a beta of 0.43. AngioDynamics has a one year low of $8.36 and a one year high of $13.99. The business has a fifty day moving average price of $10.85 and a 200-day moving average price of $11.55.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The company had revenue of $78.42 million for the quarter, compared to the consensus estimate of $76.77 million. On average, equities research analysts expect that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.